Instylla

Instylla, founded in 2017 and headquartered in the United States, is a biotechnology startup with the slogan "Materializing Solutions™️." The company is dedicated to the development of next-generation liquid embolics for interventional radiology, initially focusing on clinical applications in interventional oncology and peripheral hemostasis. It's important to note that the products are still in the investigational stage and are limited by Federal (or US) law to investigational use only, not available for sale. In its latest funding round, Instylla secured a substantial $30.00M Series C investment on 15 August 2023. The investment was participated in by a consortium of prominent venture capital firms including Catalyst Health Ventures, Ascension Ventures, Delos Capital, Excelestar Ventures, Incept LLC, Sparta Group, and AMED Ventures. This latest investment underlines the confidence and support from key industry players in the potential of Instylla's innovative solutions within the biotechnology sector.